Next Financial Group’s BridgeBio Pharma BBIO Stock Holding History

Next Financial Group’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-247	Closed	-$18K	–	2524
2020 Q4	$18K	Buy	+247	New	+$11.9K	﹤0.01%	1570

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SUT

SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Next Financial Group's BBIO Position: Q1 2021 in Review

Next Financial Group sold out of BridgeBio Pharma (BBIO) in Q1 2021, closing a stake of 247 shares — an estimated $18K sold.

Next Financial Group first reported a position in BBIO in Q4 2020 and held it in 1 quarter. The position peaked at $18K in Q4 2020. 198 funds tracked by Wall St. Rank hold BBIO as of Q1 2021.

Next Financial Group reported no remaining BridgeBio Pharma position as of Q1 2021 after selling out during the quarter.
Next Financial Group sold 247 BridgeBio Pharma shares in Q1 2021, an estimated $18K.
Next Financial Group first reported a position in BridgeBio Pharma in Q4 2020 and held it in 1 quarter.
Next Financial Group's BridgeBio Pharma position peaked at $18K in Q4 2020.
198 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2021.

Based on Next Financial Group's 13F filing for Q1 2021, filed 16 Apr 2021.